TrialAnnals of the rheumatic diseases2017

Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study.

Edward C Keystone et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.